PSY68 Dosing pattern analysis for Biologics in the treatment of Psoriasis in Canada: indication-specific information retrieved from Administrative Claims Database  by Gregory, V. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A303
effects, only 3,424 prescriptions were reimbursed. Reimbursement per prescription 
varied by state; in 2001, the national average was $107. CONCLUSIONS: Despite an 
obesity epidemic, very few states reimbursed pharmacies for weight-loss medica-
tions, including orlistat. Understanding the different decisions that the states made 
with respect to weight-loss pharmacotherapy is a goal for future research.
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OBJECTIVES: An estimated 100 million adults suffer from chronic pain in the US. 
The total cost of pain ranges from $560 to $635 billion in 2010, exceeding that of 
heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 billion). The 2011 
IOM report on pain states that effective pain management is “a moral imperative” 
for health care providers. Many pharmaceutical options are available to prescribers, 
most notably prescription opioids. Prescription opioids are analgesics which can 
be effective for the treatment of pain when monitored appropriately. Hydrocodone 
combination products are among the most commonly prescribed opioids in the 
US. The objective of this study was to perform a comprehensive literature review 
of the use and impact of hydrocodone in the US. METHODS: A comprehensive 
literature review was conducted regarding the use and impact of hydrocodone in 
the US. RESULTS: The US consumed 80% of the global supply of opioids and 99% 
of the global hydrocodone supply. From 1997 to 2007, hydrocodone use increased 
280%. Due to their potential for harm and abuse, hydrocodone combination prod-
ucts were recently rescheduled from Schedule III to Schedule II by the U.S. Food 
and Drug Administration (FDA). Single entity hydrocodone extended release was 
recently approved by the FDA and has been met with much controversy due to its 
potential for abuse. CONCLUSIONS: Hydrocodone use is highly prevalent in the 
US. Long-term use of hydrocodone and single entity hydrocodone use need to be 
actively monitored for appropriateness. Future studies should assess the impact 
of rescheduling.
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OBJECTIVES: Chronic or long-term pain disturbs numerous lives, which is one of the 
most prevalent reasons for doctor visits and reduces people’s quality of life. A com-
mon treatment for long-term non-cancer pain (CNCP) is long-term opioid therapy. 
However, the effectiveness of opioids for CNCP is still controversy and associated 
medical expenditure is vague. We investigated the impact of opioid treatment on 
the total medical expenditures for U.S. general population. METHODS: We used 
the 2011 Medical Expenditure Panel Survey, a nationally representative survey for 
health care use, expenditures and health insurance coverage of the U.S. civilian non-
institutionalized population. After excluding individuals with the priority condition 
of cancer and current diagnosis of cancer, we used response to the SF-12 question-
naire and ICD codes to identify chronic pain conditions. The final sample includes 
11,858 individuals with 355 receiving opioid treatments. We conducted bivariate 
statistical analysis to compare demographic characteristics, clinical conditions and 
total expenditures for CNCP patients’ between on- and off-opioid treatment groups. 
Using a multivariate generalized linear model (GLM), we estimated the impact of 
opioid treatment on medical care expenditures for CNCP patients, after adjusting 
for covariates. RESULTS: The bivariate analysis results show statistical significant 
differences in the use of opioid treatments associated with race/ethnicity, education 
level, smoking status, physical activity, and health status. The unadjusted mean 
total annual medical expenditures were $29,914 for opioid users and $8,564 for 
non-opioid users. The GLM regression results show the opioid treatment is associ-
ated with $3,419 to $9,120 in additional medical expenditure, after adjusting covari-
ates. CONCLUSIONS: Appropriate management for CNCP is critical to improve their 
perceived health and wellbeing and to decrease medical expenditures. However, 
due to the cross-sectional design, there might be some higher spending for opioid 
users results from unobserved patient severity, as well as no treatment outcome 
measures, which needs further study.
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OBJECTIVES: High cost biologic treatments for diseases such as plaque psoriasis, 
raise growing concerns over the increasing cost to the health care systems that 
are funding these treatments. Administrative databases can generate important 
information about the way these drugs are prescribed in a “real world” setting. The 
objectives of this analysis were to determine the initial dosing and identify dose 
escalation patterns for biologics in the treatment of psoriasis in Canada. METHODS: 
A sample of data from patients covered by the public (Quebec and Ontario) and pri-
vate drug plans in Canada, who received a biologic between January 2010 and August 
2012 for at least 12 months, were retrieved (IMS Brogan, IMS Longitudinal Claims 
Dataset, Jan 2010 - Aug 2013, reported Nov 2013). A specific algorithm was developed 
based on prescriber information and concomitant medications to capture claims 
associated to psoriasis. Dosing analysis was performed for four biologics approved 
for psoriasis in Canada: adalimumab, etanercept, infliximab and ustekinumab. Dose 
escalation was defined as a 20% dose increase above the previous dose, excluding 
induction. RESULTS: A total of 4,510 patients were identified and met inclusion 
criteria. The average first year dose was higher than years 2 and 3, consistent with 
OBJECTIVES: Although opioids play a central role in the treatment, and palliation 
of many medical conditions, there is a large and growing problem of abuse nation-
ally and in South Carolina particularly. According to the 2009 National Survey on 
Drug Use and Health, more than 5 million Americans abused prescription opioid 
painkillers in January 2011. Reports show an increase in cases of doctor shopping, 
prescription forgery, illicit prescribing and dispensing, and other diversion activi-
ties. We determine patterns of opioid prescribing in South Carolina through an 
epidemiologic analysis and geo-spatial mapping of South Carolina prescription 
data for 2010-2011. METHODS: Using de-identified data from the South Carolina 
Reporting and Identification Prescription Tracking System (SCRIPTS), we conducted 
a state-wide epidemiological analysis of patient and prescriber opioid prescribing 
patterns including distributions of number of prescriptions, number of prescribers 
and of pharmacies used by each patient. Additionally, we conducted County- and Zip 
Code-level analyses of opioid prescribing patterns. RESULTS: Prescriber deciles were 
created representing 10% groupings of prescribers based on controlled substances 
(CS) II – IV prescription volume. The top 10% of SC prescribers wrote more than 60% 
(N= 2,158,574) of the total CS II – IV prescriptions in 2010, and 58% of total opioid 
prescriptions. The top pharmacy decile dispensed about 44% of total prescriptions 
and about 37% of opioid prescriptions. Five Zip Codes had the highest percent of 
opioid prescriptions out of total prescriptions (Charleston, Richland, Greenville, 
Barnwell and Aiken). In 2010 counties with the highest percent of prescriptions 
(> 61%) were Greenville, Richland, Barnwell and Charleston, whereas in 2011 the 
counties with the highest percent of prescriptions were Greenville, Chester, Richland 
and Charleston. CONCLUSIONS: Our findings indicate a relatively small percentage 
of providers, concentrated in a few counties, account for most opioid prescriptions. 
This group represents a potential target for physician education and engagement 
in handling pain management and appropriate use of opioids.
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OBJECTIVES: Many chronic users of immediate-release opioids (IROs) initiating 
treatment with extended-release opioids (EROs) are steered towards generic options, 
even if switching molecules is required. Switching may introduce uncertainty for 
patients regarding dosing, titration and efficacy. This study assessed treatment 
patterns among patients chronically-treated with IR oxycodone who initiate ERO 
treatment, and describes differences between patients initiating treatment on 
the same molecule and those who switch molecules. METHODS: Commercially-
insured patients aged < 65 were selected from de-identified OptumHealth Reporting 
and Insights claims data, 2011-2014. Chronic IR oxycodone users were defined as 
patients with ≥ 2 continuous prescriptions and ≥ 60 days supply leading up to initia-
tion of ERO treatment (index). Patients were excluded if they had claims for EROs 
during a 6-month baseline period or possible opioid replacement therapy (metha-
done/buprenorphine) during the 6-month follow-up period, and were required to 
be continuous users of opioids throughout follow-up. The sample was stratified 
based on whether ER therapy was initiated on the same molecule (ER oxycodone) 
or different molecules. Treatment patterns and pill count were assessed for both 
cohorts. RESULTS: During baseline, 2,318 chronic IR oxycodone users initiating 
EROs were identified, with 933 (40%) initiating ER oxycodone and the remainder 
switching molecules. Same-molecule patients were more likely to continuously 
use index therapy (41.9% vs. 33.6%), and less likely to switch to a different ERO 
(12.3% vs. 26.0%). Among different-molecule patients switching EROs, nearly half 
switched to ER oxycodone. Concomitant use of IR oxycodone was observed in both 
groups, but continuous index ERO users in the same-molecule cohort saw a greater 
decline in IR pill count compared with the different-molecule cohort (-173.3 vs. 
-105.9). CONCLUSIONS: Chronic IR oxycodone patients initiating EROs on the same 
molecule were more likely to remain on index treatment, and those remaining on 
treatment experienced a greater decline in IR oxycodone pill count.
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OBJECTIVES: More than one third of adults in the U.S. are considered obese (body 
mass index ≥ 30kg/m2). Because of their relatively low socioeconomic status, the 
Medicaid population is disproportionately affected by obesity. The objective was to 
compare the utilization of and spending on anti-obesity medication, specifically 
orlistat (amphetamine-based weight-loss drugs were highly restricted by Medicaid 
because of their potential for abuse), by state Medicaid programs from 1999-2013. 
Orlistat, approved by the FDA in April 1999, is a gastric and pancreatic lipase inhibi-
tor that reduces dietary fat absorption. METHODS: Using the individual state files 
for Medicaid outpatient drug utilization maintained by the Centers for Medicare 
and Medicaid Services, quarterly utilization and (pre-rebate) expenditure data 
from 1999-2013 were extracted for all branded and generic orlistat prescriptions 
for Medicaid beneficiaries. Descriptive statistics were computed. RESULTS: In 1999, 
North Carolina reimbursed 5,242 prescriptions; Louisiana 3,712 prescriptions; and 
Wisconsin 1,460. Subsequently, several other states, such as California, Connecticut, 
Kentucky, Minnesota, New Jersey, and Pennsylvania came on board with a fairly large 
number of prescriptions reimbursed (6,041 in California in 2003). In other states, like 
Ohio and New York, no orlistat prescriptions were reimbursed until the last years of 
the study, most likely representing a policy shift. In 2001,when Medicaid utilization 
was at its peak, a total of 87,811 prescriptions were reimbursed across the country. 
By 2013, due to several factors including an over-the-counter version of orlistat 
approved by the FDA in 2010 and a loss in popularity due to gastrointestinal side 
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By disease: ischemic heart disease, 1.9 times or 10 days longer; hypertension 1.3 times 
or 4 days longer; congestive heart failure, 1.2 times or 3 days longer; and rheumatoid 
arthritis, 1.4 times or 2 days longer. Obese patients with diabetes and s/p cerebral 
vascular accident had a shorter LOS (0.8 times or 3 days, and 0.8 times or 4 days 
respectively). CONCLUSIONS: Obesity increases the LOS for all-cause hospital admis-
sions among patients with various underlying chronic diseases. This may be due to 
insufficient diagnosis by the primary provider or specialist, inadequate medication 
dosing (eg, pain management), or inadequate support during an inpatient stay. A 
proactive health care policy is needed to guide the management of patients with 
chronic disease who are also obese, with the potential for cost-savings of interven-
tional, pharmaceutical, or surgical treatment of obesity at baseline.
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OBJECTIVES: The aim of the present analysis was to identify the level of the availabil-
ity and total expenditure of medicines for rare diseases with European authorization 
and orphan designation. In Poland all innovative medical technologies and services 
claiming public money founding have to be assessed by Agency for Health Technology 
Assessment (AOTM). Pharmacoeconomic evaluations of new therapies are required 
for all reimbursement decisions and orphan drug manufacturers cannot be exempted 
from providing a full pharmacoeconomic or HTA reports. The criteria of assessment 
connected with clinical and cost effectiveness (threshold is 3xGDP for ICUR/QALY) 
are the same for all kind of drugs. METHODS: All orphan designation admitted by 
European Medicines Agency (EMA) until the end of 2014 were reviewed and analyzed 
from the official website of EMA. Among 792 EMA’s orphan registrations studied 78 
(9,8%) applied to orphan drugs. We compared the outcomes with reimbursement list 
officially published by Ministry of Health. Then it was checked what was the share of 
orphan drugs in overall reimbursement spending. RESULTS: At the end of 2014 there 
were 28 orphan drugs available on the reimbursement list (36% of designed by EMA). 
The total public payer reimbursement spending was € 2.41bn in 2012 and € 2.26bn in 
2013. Orphan drugs have only accounted for a small percentage of the overall drug 
budget in polish health care system (1,5% in 2012 and 3,2% in 2013). CONCLUSIONS: 
In the literature we can find opinions that the relatively low budget impact of orphan 
drugs is often used as an argument in reimbursement decisions. In Poland reimburse-
ment was awarded to the minority of orphan drugs designed by EMA. Very strict 
requirements in order to ensure compatibility with law directives could potentially 
influence negative reimbursement decisions for orphan drugs.
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BACKGROUND: Obesity is a pathology that leads to several co-morbidities such as 
diabetes and hypertension. In Brazil obesity rates (BMI > 30kg/m2) raised from 11.8% 
in 2006 to 17.5% in 2013. Bariatric Surgery is the most effective treatment to achieve 
excess weight lost for morbid patients. It is estimated that Brazil has around 1.8 
million people with BMI > 40kg/m2, considering that Brazil has an universal health 
care system and 25% of the population relies in the private health care sector, sev-
eral people are eligible to get bariatric surgery OBJECTIVES: Evaluate the use of the 
resources dedicated to treat morbid obese patients in the Brazilian public health 
care system (SUS) from 2008 to 2013 METHODS: Revised data of expenditures, num-
ber of surgeries and length of stay related to bariatric surgery in the database of the 
IT Department of SUS (DATASUS) RESULTS: The number of certified hospitals that 
perform bariatric surgery increased by 35% and the percentage of states covered 
by certified hospitals rose from 60% to 74%. During the same period the number of 
procedures increased by 113%. Despite the increase in the number of procedures 
by 113%, the days of hospitalization required for surgeries increased only 52%; this 
is due the average length of stay reduction from 5.7 days to 4.1 days, showing a 
better efficiency among hospitals. The total expenditure in bariatric surgeries rose 
by 161%. CONCLUSIONS: Analysis demonstrated that the access to the bariatric 
procedure in Brazil has increased in the past five years. The hospitals’ efficiency 
improved during the same period, decreasing the average length of stay. Today 
the Brazilian public health care system provides surgery to less than 0.75% of the 
eligible population and despite the access increase; more resources (physicals and 
infrastructure) are needed in order to treat the morbid obese population
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OBJECTIVES: To describe treatment patterns and cost in patients with PSO (psoria-
sis) receiving biologic therapies (BT). METHODS: A retrospective cohort of medica-
tion claims data from IMS Brogan Private (Canadian national) and Public (Ontario 
and Quebec) Drug Plan databases was analysed. Biologic-naïve PSO patients > 18 
years of age were selected between 01/01/2007 and 03/30/2011 and followed for 
24 months to understand lines of therapy, retention on BT, and annual therapy 
costs. Target biologics included adalimumab, etanercept, infliximab and usteki-
numab. RESULTS: 3,546 patients were identified. Of those, 44% initiated etanercept, 
26% adalimumab, 19% ustekinumab, and 10% infliximab. 32% of patients remained 
on 1st line therapy, 16% switched, and 52% stopped therapy over the 24 month 
period. Median days on 1st line therapy was longer in public than private plans (502 
vs. 357). Of those who switched, 556 received 2 lines, and 105 received 3 or more lines 
of BT. In a retention model of private plan patients, those who supplemented with 
non-biologic PSO therapies were 16% - 42% more likely to stay on BT than those tak-
the induction period for each drug. Overall, 63% of patients experienced a dose 
escalation, of which 68% occurred within the first year, excluding induction. Peak 
frequency of dose escalation occurred between weeks 11-30. Calculated daily, esca-
lated dose was greater than maintenance by 9% for adalimumab, 14% for etanercept, 
and 28% for ustekinumab. CONCLUSIONS: Across all treatments, dose escalation 
was recorded in over 60% of patients, most often in the first year of treatment, 
indicating that patients may require additional doses to maintain response. These 
data highlight the need for new treatments which provide high sustained efficacy, 
with a rapid onset of action.
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OBJECTIVES: To quantify the effect of the implementation of Florida’s PMP and 
pill mill laws on overall and high risk opioid prescribing, utilization, and dispens-
ing. METHODS: We applied comparative interrupted time series analyses to IMS 
Health LRx LifeLink data to characterize the effect of PMP and pill mill law imple-
mentation on a closed cohort of patients, prescribers and retail pharmacies between 
July 2010 and Sept 2012 in Florida (intervention state) compared with Georgia (con-
trol state). We conducted numerous sensitivity analyses including varying the 
length of observation and modifying requirements for continuous observation of 
individuals throughout the study period. RESULTS: From July 2010 to September 
2012, a cohort of 2.6 million patients, 431,890 prescribers and 2,829 pharmacies was 
associated with approximately 480 million prescriptions in Florida and Georgia, 
8% of which were for opioids. Average total monthly opioid volume (355.1 vs. 124.2 
kilograms [kg]), average dose per transaction (55.2 vs. 46.6 milligrams [mg] MEDD), 
and average number of days supply (18.4 vs. 16.0 days) were each higher in Florida 
than Georgia prior to implementation of Florida’s PMP and pill mill laws. Overall, 
Florida’s laws were associated with statistically significant declines in opioid volume 
(3.7 kilograms/month) and MEDD (0.46 mg/month), without any change in days 
supply. Reductions were limited to prescribers and patients with the highest base-
line opioid prescribing and utilization, respectively. Sensitivity analyses varying the 
time windows and enrollment criteria supported the main results. CONCLUSIONS: 
Implementation of PMP and pill mill laws in Florida was associated with decreases 
in prescription opioid dispensing relative to Georgia among patients and providers 
with high levels of opioid utilization at baseline.
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OBJECTIVES: Hemophilia is an inherited condition requiring lifelong, expensive 
treatment. Initiating prophylaxis treatment with factors VIII (hemophilia A) or 
IX (hemophilia B) at an early age has been shown to be effective in improving 
health outcomes. In 2007 the medical advisory council of the National Hemophilia 
Foundation (NHF’s MASAC) recommended prophylaxis treatment as the optimal 
therapy for these patients. The study objectives were:(1) To explore the economic 
burden over the patient’s lifespan; (2) To quantify changes in factor VIII/IX utilization 
and related costs over the past decade. METHODS: A retrospective, US health insur-
ance claim database (2004-2012) analysis was conducted. Males with ≥ 2 pharmacy 
claims for a hemophilia drug within 3 months, and continuous enrollment for ≥ 180 
days were included. Patients utilizing inhibitor treatments were excluded. Annual 
payer and patient out-of-pocket (OOP) expenses were calculated by service category 
(inpatient, outpatient, medications), and stratified by patient’s age and calendar 
year. Costs were adjusted to 2013USD. Annual supply days (ASD) per patient were 
calculated; ASDs over time were compared using a t-test. RESULTS: For hemophilia 
A (N= 727), increase in payers’ costs was observed during the first 4 decades of life, 
peaking at age 34 ($273,669) decreasing thereafter, and annual OOP staying constant 
at $2,589/year. For hemophilia B (N= 161), an increase in payers’ costs was observed 
during the first 3 decades of life peaking at age 29 ($281,981) decreasing thereafter 
with annual OOP at $2,401/year. Between 2007 and 2012, ASD per patient increased 
significantly for both factor VIII (ADVATE®: 160.5 vs. 249.9 days, p= 0.00029) and 
factor IX (BENEFIX®: 132.8 vs. 214.7 days, p= 0.0255) coinciding with payers’ drugs 
cost over the same time period. (Hemophilia A: $186,283 to $212,747respectively; 
hemophilia B: $147,778 to $186,851 respectively). CONCLUSIONS: Over the past dec-
ade, the mean per patient consumption of factor replacement therapy has increased 
substantially, in line with new treatment guidelines.
PSY71
increaSed LengtH of StaY for obeSe PatientS bY cHronic diSeaSe
Hoshen M.B., Leventer-Roberts M., Balicer R.
Clalit Research Institute, Tel Aviv, Israel
OBJECTIVES: An obese body mass index (BMI) increases morbidities, however there 
are few chronic disease registries that can quantify the cost of obesity. Clalit Health 
Services (CHS), with complete longitudinal data of over 4 million members, provides 
an ideal format for comparing health care utilization between obese and non-obese 
patients to inform the need for improved health care policy. METHODS: For the years 
2011-2013 inclusive, we took two random samples of 10,000 obese (BMI> 30) patients 
and 10,000 normal and underweight (BMI< = 25) from the CHS database both accord-
ing to Clalit population age standard. We then extracted their additional chronic 
diseases from the CHS registry. Finally, we compared the average length of stay (LOS) 
for inpatient admissions between the groups, by disease. RESULTS: Obese patients 
with underlying chronic disease had, on average, a 27% increased LOS compared to 
non-obese patients with chronic disease. The greatest effect was seen among obese 
patients with chronic renal failure, whose LOS was 2.7 times or nearly 20 days longer. 
